FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307568286> ?p ?o ?g. }

• W4307568286 endingPage "637" @default.
• W4307568286 startingPage "627" @default.
• W4307568286 abstract "Kidney transplant survival is shortened by chronic rejection and side effects of standard immunosuppressive drugs. Cell-based immunotherapy with tolerogenic dendritic cells has long been recognized as a promising approach to reduce general immunosuppression. Published trials report the safety and the absence of therapy-related adverse reactions in patients treated with tolerogenic dendritic cells suffering from several inflammatory diseases. Here, we present the first phase I clinical trial results using human autologous tolerogenic dendritic cells (ATDC) in kidney transplantation. Eight patients received ATDC the day before transplantation in conjunction with standard steroids, mycophenolate mofetil and tacrolimus immunosuppression with an option to taper mycophenolate mofetil. ATDC preparations were manufactured in a Good Manufacturing Practice-compliant facility and fulfilled cell count, viability, purity and identity criteria for release. A control group of nine patients received the same standard immunosuppression, except basiliximab induction replaced ATDC therapy and mycophenolate tapering was not allowed. During the three-year follow-up, no deaths occurred and there was 100% graft survival. No significant increase of adverse events was associated with ATDC infusion. Episodes of rejection were observed in two patients from the ATDC group and one patient from the control group. However, all rejections were successfully treated by glucocorticoids. Mycophenolate was successfully reduced/stopped in five patients from the ATDC group, allowing tacrolimus monotherapy for two of them. Regarding immune monitoring, reduced CD8 T cell activation markers and increased Foxp3 expression were observed in the ATDC group. Thus, our results demonstrate ATDC administration safety in kidney-transplant recipients." @default.
• W4307568286 created "2022-11-03" @default.
• W4307568286 creator A5000832841 @default.
• W4307568286 creator A5002582169 @default.
• W4307568286 creator A5002644565 @default.
• W4307568286 creator A5003722044 @default.
• W4307568286 creator A5004645920 @default.
• W4307568286 creator A5005455170 @default.
• W4307568286 creator A5012515774 @default.
• W4307568286 creator A5014572019 @default.
• W4307568286 creator A5015103954 @default.
• W4307568286 creator A5015283577 @default.
• W4307568286 creator A5016027333 @default.
• W4307568286 creator A5018445018 @default.
• W4307568286 creator A5020775252 @default.
• W4307568286 creator A5025108864 @default.
• W4307568286 creator A5025848614 @default.
• W4307568286 creator A5025912989 @default.
• W4307568286 creator A5031278762 @default.
• W4307568286 creator A5036412074 @default.
• W4307568286 creator A5038976558 @default.
• W4307568286 creator A5040930081 @default.
• W4307568286 creator A5041476657 @default.
• W4307568286 creator A5043007943 @default.
• W4307568286 creator A5043305493 @default.
• W4307568286 creator A5043842591 @default.
• W4307568286 creator A5043964486 @default.
• W4307568286 creator A5047490177 @default.
• W4307568286 creator A5050918772 @default.
• W4307568286 creator A5052951076 @default.
• W4307568286 creator A5054644601 @default.
• W4307568286 creator A5055007301 @default.
• W4307568286 creator A5058743965 @default.
• W4307568286 creator A5061969978 @default.
• W4307568286 creator A5063959534 @default.
• W4307568286 creator A5064480532 @default.
• W4307568286 creator A5068990956 @default.
• W4307568286 creator A5069484604 @default.
• W4307568286 creator A5072837552 @default.
• W4307568286 creator A5077457122 @default.
• W4307568286 creator A5082182356 @default.
• W4307568286 creator A5084637045 @default.
• W4307568286 creator A5088148467 @default.
• W4307568286 creator A5089422245 @default.
• W4307568286 creator A5090737978 @default.
• W4307568286 date "2023-03-01" @default.
• W4307568286 modified "2023-10-06" @default.
• W4307568286 title "A Phase I/IIa study of autologous tolerogenic dendritic cells immunotherapy in kidney transplant recipients" @default.
• W4307568286 cites W1543497746 @default.
• W4307568286 cites W1850465101 @default.
• W4307568286 cites W1918052238 @default.
• W4307568286 cites W1936829300 @default.
• W4307568286 cites W1937605809 @default.
• W4307568286 cites W1972758309 @default.
• W4307568286 cites W2010912590 @default.
• W4307568286 cites W2030568584 @default.
• W4307568286 cites W2041593156 @default.
• W4307568286 cites W2055860642 @default.
• W4307568286 cites W2060070176 @default.
• W4307568286 cites W2071282292 @default.
• W4307568286 cites W2116741625 @default.
• W4307568286 cites W2117477752 @default.
• W4307568286 cites W2122532904 @default.
• W4307568286 cites W2125956827 @default.
• W4307568286 cites W2151829671 @default.
• W4307568286 cites W2180435160 @default.
• W4307568286 cites W2326577657 @default.
• W4307568286 cites W2346566986 @default.
• W4307568286 cites W2561134207 @default.
• W4307568286 cites W2617374738 @default.
• W4307568286 cites W2791703022 @default.
• W4307568286 cites W2884498786 @default.
• W4307568286 cites W2938726064 @default.
• W4307568286 cites W2992218627 @default.
• W4307568286 cites W3023984174 @default.
• W4307568286 cites W3026232934 @default.
• W4307568286 cites W3026253194 @default.
• W4307568286 cites W3094128707 @default.
• W4307568286 cites W3100659075 @default.
• W4307568286 cites W3100988608 @default.
• W4307568286 doi "https://doi.org/10.1016/j.kint.2022.08.037" @default.
• W4307568286 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36306921" @default.
• W4307568286 hasPublicationYear "2023" @default.
• W4307568286 type Work @default.
• W4307568286 citedByCount "1" @default.
• W4307568286 countsByYear W43075682862023 @default.
• W4307568286 crossrefType "journal-article" @default.
• W4307568286 hasAuthorship W4307568286A5000832841 @default.
• W4307568286 hasAuthorship W4307568286A5002582169 @default.
• W4307568286 hasAuthorship W4307568286A5002644565 @default.
• W4307568286 hasAuthorship W4307568286A5003722044 @default.
• W4307568286 hasAuthorship W4307568286A5004645920 @default.
• W4307568286 hasAuthorship W4307568286A5005455170 @default.
• W4307568286 hasAuthorship W4307568286A5012515774 @default.
• W4307568286 hasAuthorship W4307568286A5014572019 @default.
• W4307568286 hasAuthorship W4307568286A5015103954 @default.
• W4307568286 hasAuthorship W4307568286A5015283577 @default.
• W4307568286 hasAuthorship W4307568286A5016027333 @default.

• next